The outcome of COVID-19 in patients with hematological malignancy

Abstract

In this study, we aim to report the outcomes for COVID-19 in patients with hematological malignancy in Turkey. Data from laboratory-confirmed 188 897 COVID-19 patients diagnosed between 11 March 2020 and 22 June 2020 included in the Republic of Turkey, Ministry of Health database were analyzed retrospectively. All COVID-19 patients with hematological malignancy (n = 740) were included in the study and an age, sex, and comorbidity-matched cohort of COVID-19 patients without cancer (n = 740) at a 1:1 ratio was used for comparison. Non-Hodgkin lymphoma (30.1%), myelodysplastic syndrome (19.7%), myeloproliferative neoplasm (15.7%) were the most common hematological malignancies. The rates of severe and critical disease were significantly higher in patients with hematological malignancy compared with patients without cancer (P = .001). The rates of hospital and intensive care unit (ICU) admission were higher in patients with hematological malignancy compared with the patients without cancer (P = .023,P = .001, respectively). The length of hospital stay and ICU stay was similar between groups (P = .7,P = .3, retrospectively). The rate of mechanical ventilation (MV) support was higher in patients with hematological malignancy compared with the control group (P = .001). The case fatality rate was 13.8% in patients with hematological malignancy, and it was 6.8% in the control group (P = .001). This study reveals that there is an increased risk of COVID-19-related serious events (ICU admission, MV support, or death) in patients with hematological malignancy compared with COVID-19 patients without cancer and confirms the high vulnerability of patients with hematological malignancy in the current pandemic.

C1 [Yigenoglu, Tugce N.; Altuntas, Fevzi; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Dept Hematol, Ankara, Turkey.

[Yigenoglu, Tugce N.; Altuntas, Fevzi; Basci, Semih; Dal, Mehmet Sinan] Univ Hlth Sci, Ankara Oncol Training & Res Hosp, Bone Marrow Transplantat Ctr, Ankara, Turkey.

[Ata, Naim] Minist Hlth, Dept Strategy Dev, Ankara, Turkey.

[Korkmaz, Serdal] Univ Hlth Sci, Kayseri Training & Res Hosp, Dept Hematol, Kayseri, Turkey.

[Namdaroglu, Sinem] Univ Hlth Sci, Bozyaka Training & Res Hosp, Dept Hematol, Izmir, Turkey.

[Basturk, Abdulkadir] Selcuk Univ, Sch Med, Dept Internal Med, Div Hematol, Konya, Turkey.

[Hacibekiroglu, Tuba] Sakarya Univ, Sch Med, Dept Internal Med, Div Hematol, Sakarya, Turkey.

[Dogu, Mehmet H.] Istanbul Training & Res Hosp, Dept Hematol, Istanbul, Turkey.

[Erkurt, Mehmet A.] Inonu Univ, Sch Med, Dept Internal Med, Div Hematol, Malatya, Turkey.

[Dal, Kursat] Kecioren Training & Res Hosp, Dept Internal Med, Ankara, Turkey.

[Turgut, Burhan] Namik Kemal Univ, Sch Med, Dept Internal Med, Div Hematol, Tekirdag, Turkey.

[Ulgu, Mustafa Mahir; Imrat, Ersan] Minist Hlth, Gen Directorate Hlth Informat Syst, Ankara, Turkey.

[Celik, Osman] Minist Hlth, Publ Hosp Gen Directorate, Ankara, Turkey.

[Birinci, Suayip] Minist Hlth, Ankara, Turkey.